<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104052</url>
  </required_header>
  <id_info>
    <org_study_id>P02538: Part 1</org_study_id>
    <nct_id>NCT00104052</nct_id>
  </id_info>
  <brief_title>Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)</brief_title>
  <official_title>Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety, efficacy and tolerability of the combination
      of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary
      objective is to measure the multiple-dose pharmacokinetics of PEG-Intron and REBETOL in
      pediatric subjects with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This global, multicenter, open-label Phase 3 study will evaluate the safety, efficacy and
      tolerability of PEG-Intron plus REBETOL in previously untreated pediatric subjects, ages 3
      through 17 years, with chronic hepatitis C.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment</measure>
    <time_frame>Up to 48-week treatment duration. Follow-up of 24 weeks.</time_frame>
    <description>SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (PEG2b) (SCH 54031)</intervention_name>
    <description>PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.</description>
    <arm_group_label>PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)</arm_group_label>
    <other_name>PEG-Intron (SCH 54031)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (SCH 18908)</intervention_name>
    <description>15 mg/kg/day for up to 48 weeks</description>
    <arm_group_label>PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)</arm_group_label>
    <other_name>REBETOL (SCH 18908)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 3-17 years old

          -  Individuals weighing ≤ 90 kg

          -  Previously untreated children with chronic hepatitis C (HCV RNA qPCR plasma positive)

          -  Individuals with any HCV (hepatitis C virus) genotype

          -  Hematology laboratory results of:

               -  Hemoglobin (HGB) ≥ 11 g/dL for females or ≥ 12g/dL for males,

               -  White Blood Cell Count (WBC) ≥ 3,000/mm^3,

               -  Neutrophils ≥ 1,500/mm^3,

               -  Platelets ≥ 100,000/mm^3

          -  Chemistry laboratory results of:

               -  Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and Bilirubin,

               -  Antinuclear antibody (ANA) ≤ 1:160,

               -  Fasting Glucose 70-140 mg/dL. Note: If glucose levels are between 116-140 mg/dL
                  or an individual has diabetes, HbA1C must be ≤ 8.5%

          -  Compensated liver disease

          -  Historic or pre-treatment liver biopsy slides available

          -  No significant co-existing psychiatric disease

          -  Those with diabetes, hypertension, or birth prior to 32 weeks gestational age must
             have normal eye exams and retinal photographs (these will be done as part of the study
             before hepatitis C treatment is given)

          -  Patients and partners of patients willing to use adequate contraception during the
             course of the study

          -  Abstain from alcohol and any other illicit drugs

        Exclusion Criteria:

          -  Serum ALT &gt;10 times the upper limit of normal within the 6 months prior to study

          -  Previous hepatitis C treatment

          -  Children with liver disease not caused by hepatitis C

          -  Most recent liver biopsy is normal

          -  Individuals infected with the hepatitis B virus and/or human immunodeficiency virus
             (HIV)

          -  Known blood disorders such as hemoglobinopathy, coagulopathy, or G6PD deficiency

          -  Known immunodeficiency disorders requiring immunoglobulin therapy

          -  Body organ transplant

          -  Any known or suspected cancer within the past 5 years

          -  Children with chronic pulmonary disease

          -  Individuals who have a medical condition that would likely require systemic steroids

          -  Those with a history of central nervous system (CNS) trauma or seizure disorders

          -  Individuals with pre-existing psychiatric disorders including but not limited to
             moderate to severe depression

          -  Current or previous use of lithium or antipsychotic drugs

          -  Patients with clinically significant electrocardiogram (ECG) abnormalities and/or
             significant cardiovascular dysfunction (e.g., angina, congestive heart failure, recent
             myocardial infarction, uncontrolled hypertension, significant arrhythmia, cardiac
             sequelae from Kawasaki disease, cardiomyopathy, and/or history of congenital heart
             disease)

          -  Insulin-dependent diabetes mellitus or poorly controlled non-insulin dependent
             diabetes mellitus

          -  Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease,
             ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenic purpura,
             systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe
             psoriasis, or symptomatic thyroid disorder)

          -  History of substance abuse, including alcohol (e.g., binge drinking, blackouts),
             intravenous drugs and inhaled drugs

          -  Subjects who have a history of pregnancy or who are pregnant and/or breast feeding.
             Subjects who intend to become pregnant during the study period. Subjects with partners
             who intend to become pregnant during the study period

          -  Subjects with clinically significant retinal abnormalities such as known retinopathy
             of prematurity or other retinopathies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2005</study_first_submitted>
  <study_first_submitted_qc>February 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2005</study_first_posted>
  <results_first_submitted>November 14, 2008</results_first_submitted>
  <results_first_submitted_qc>February 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2009</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG-Intron Plus REBETOL</title>
          <description>SCH 54031 PEG-Intron (peginterferon alfa-2b) 60 µg/m2 subcutaneous injection once weekly plus SCH 18908 REBETOL (ribavirin) 15 mg/kg PO daily in two divided doses for 48 weeks for subjects with Genotypes 1,4,5,6 and high-viral-load (≥600,000 IU/mL) Genotype 3 subjects. For subjects with Genotype 2 or low-viral-load Genotype 3 (&lt;600,000 IU/mL), the same treatment will be given for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation unrelated to treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG-Intron Plus REBETOL</title>
          <description>SCH 54031 PEG-Intron (peginterferon alfa-2b) 60 µg/m2 subcutaneous injection once weekly plus SCH 18908 REBETOL (ribavirin) 15 mg/kg PO daily in two divided doses for 48 weeks for subjects with Genotypes 1,4,5,6 and high-viral-load (≥600,000 IU/mL) Genotype 3 subjects. For subjects with Genotype 2 or low-viral-load Genotype 3 (&lt;600,000 IU/mL), the same treatment will be given for 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment</title>
        <description>SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment</description>
        <time_frame>Up to 48-week treatment duration. Follow-up of 24 weeks.</time_frame>
        <population>Carry Forward analysis of participants who received at least one dose of study medication. This dataset includes one subject with undetectable HCV-RNA at Follow-up Week 12 (FW 12) but missing data at FW 24; this subject was considered a sustained responder in the Carry Forward analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron Plus REBETOL</title>
            <description>SCH 54031 PEG-Intron (peginterferon alfa-2b) 60 µg/m2 subcutaneous injection once weekly plus SCH 18908 REBETOL (ribavirin) 15 mg/kg PO daily in two divided doses for 48 weeks for subjects with Genotypes 1,4,5,6 and high-viral-load (≥600,000 IU/mL) Genotype 3 subjects. For subjects with Genotype 2 or low-viral-load Genotype 3 (&lt;600,000 IU/mL), the same treatment will be given for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment</title>
          <description>SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment</description>
          <population>Carry Forward analysis of participants who received at least one dose of study medication. This dataset includes one subject with undetectable HCV-RNA at Follow-up Week 12 (FW 12) but missing data at FW 24; this subject was considered a sustained responder in the Carry Forward analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Normal approximation to the binomial</param_type>
            <param_value>0.654</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.564</ci_lower_limit>
            <ci_upper_limit>0.744</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG-Intron Plus REBETOL</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CARBON MONOXIDE POISONING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="61" subjects_affected="35" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="58" subjects_affected="28" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="22" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="76" subjects_affected="36" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="40" subjects_affected="16" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="58" subjects_affected="23" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="125" subjects_affected="32" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="51" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="50" subjects_affected="31" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="42" subjects_affected="16" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="617" subjects_affected="86" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="34" subjects_affected="24" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="70" subjects_affected="18" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="100" subjects_affected="20" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="28" subjects_affected="11" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="410" subjects_affected="71" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>NERVOUSNESS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

